Company · implicit-bioscience-57e7e6c2
Implicit Bioscience
4 sourcescompanies-2026-11-14-0.1.0
Cite this record
ConductScience Library. Implicit Bioscience. Companies, record implicit-bioscience-57e7e6c2. Release companies-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/companies/implicit-bioscience-57e7e6c2
On this page
Company
The name as ClinicalTrials.gov gives it. A company is a name ClinicalTrials.gov classes as industry, and spellings that differ only in case or spacing are one; no subsidiary is folded into a parent. A trial of two phases counts in both, and recruiting trials count as active.
- Name
- Implicit Bioscience
- Trials
- 12
- As lead sponsor
- 11
- As collaborator
- 1
- Recruiting
- 1
- Active, recruiting or not
- 3
- Completed
- 2
- Stopped early, withdrawn or suspended
- 5
- Posted results
- 1
- Trials by phase
- Phase 1 4, Phase 2 9
- Drugs its trials test
- 2
- Comparisons calculated in its trials
- 2
- First trial registered
- 2017-01-11
- Last update
- 2026-07-29
Source ClinicalTrials.gov
Pipeline2
The drugs its trials test, by the trial links the pipelines release's checks show. The phase is the highest phase those trials registered on ClinicalTrials.gov, not a development stage. Highest phase first, then the most trials.
| Drug | Highest phase registered | Trials | As lead sponsor | Recruiting | Targets | Mechanism | In Drugs and targets | Source |
|---|---|---|---|---|---|---|---|---|
| IC14 | Phase 2 | 11 | 11 | 1 | CD14 | Monocyte differentiation antigen CD14 inhibitor | https://conductscience.org/library/drugs/CHEMBL2109330 | Open Targets |
| REMDESIVIR | Phase 2 | 1 | 0 | 0 | https://conductscience.org/library/drugs/CHEMBL4065616 | Open Targets |
Trials12
The trials that name the company as lead sponsor or collaborator, newest registered first. Results posted are as ClinicalTrials.gov gave them on the day of the sponsors capture.
| Trial | Title | Role | Phase | Status | Type | Participants | Start | Results first posted | Drugs | In Trials | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06678074 | Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI | Lead sponsor | Phase 1/2 | Active, not recruiting | Interventional | 10 | 2025-02-06 | IC14 | https://conductscience.org/library/trials/NCT06678074 | ClinicalTrials.gov | |
| NCT06556810 | IC14 for Treatment of Acute Decompensated Heart Failure | Lead sponsor | Phase 1/2 | Active, not recruiting | Interventional | 10 | 2024-10-17 | IC14 | https://conductscience.org/library/trials/NCT06556810 | ClinicalTrials.gov | |
| NCT06513949 | Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients | Lead sponsor | Phase 2 | Recruiting | Interventional | 56 | 2026-06-17 | IC14 | https://conductscience.org/library/trials/NCT06513949 | ClinicalTrials.gov | |
| NCT06275893 | IC14 (Atibuclimab) in Arrhythmogenic Cardiomyopathy | Lead sponsor | Phase 1/2 | Completed | Interventional | 1 | 2024-03-29 | IC14 | https://conductscience.org/library/trials/NCT06275893 | ClinicalTrials.gov | |
| NCT04391309 | COVID-19 and Anti-CD14 Treatment Trial | Collaborator | Phase 2 | Terminated | Interventional | 49 | 2021-04-12 | 2023-06-15 | REMDESIVIR | https://conductscience.org/library/trials/NCT04391309 | ClinicalTrials.gov |
| NCT04346277 | Compassionate Use Open-Label Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19) | Lead sponsor | No longer available | Expanded access | IC14 | https://conductscience.org/library/trials/NCT04346277 | ClinicalTrials.gov | ||||
| NCT04309604 | IC14 for ALS Patients Expanded Access | Lead sponsor | No longer available | Expanded access | IC14 | https://conductscience.org/library/trials/NCT04309604 | ClinicalTrials.gov | ||||
| NCT03875560 | IC14 in Adult Patients With Dengue Fever | Lead sponsor | Phase 2 | Withdrawn | Interventional | 0 | 2019-05 | IC14 | https://conductscience.org/library/trials/NCT03875560 | ClinicalTrials.gov | |
| NCT03508453 | IC14 for Treatment of Amyotrophic Lateral Sclerosis | Lead sponsor | Phase 2 | Withdrawn | Interventional | 0 | 2021-08-15 | IC14 | https://conductscience.org/library/trials/NCT03508453 | ClinicalTrials.gov | |
| NCT03487263 | Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease | Lead sponsor | Phase 1 | Completed | Interventional | 10 | 2017-10-01 | IC14 | https://conductscience.org/library/trials/NCT03487263 | ClinicalTrials.gov |
1 to 10 of 12
See all 12 trialsConditions25
The conditions its trials name, as the trials write them, with case and spacing folded. The most trials first.
| Condition | Trials |
|---|---|
| Amyotrophic Lateral Sclerosis | 4 |
| Acute Respiratory Distress Syndrome | 2 |
| Motor Neuron Disease | 2 |
| ACM | 1 |
| ARDS, Human | 1 |
| ARVC | 1 |
| Acute Decompensated Heart Failure | 1 |
| Acute Lung Injury | 1 |
| Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) | 1 |
| Adult Respiratory Distress Syndrome | 1 |
1 to 10 of 25Source ClinicalTrials.gov
See all 25 conditionsPartners9
The other organizations its trials name, as lead sponsor or collaborator, with the class ClinicalTrials.gov gives each. The most trials shared first. A partner that is a company opens its own record.
| Organization | Class | Trials shared | In Companies | Source |
|---|---|---|---|---|
| University of Virginia | Other | 2 | ClinicalTrials.gov | |
| University of Washington | Other | 2 | ClinicalTrials.gov | |
| Massachusetts General Hospital | Other | 1 | ClinicalTrials.gov | |
| National Institute of Allergy and Infectious Diseases (NIAID) | NIH | 1 | ClinicalTrials.gov | |
| PPD Development, LP | Industry | 1 | https://conductscience.org/library/companies/ppd-development-lp-816c330d | ClinicalTrials.gov |
| Royal Brisbane and Women's Hospital | Other government | 1 | ClinicalTrials.gov | |
| Vanderbilt University Medical Center | Other | 1 | ClinicalTrials.gov | |
| Virginia Commonwealth University | Other | 1 | ClinicalTrials.gov | |
| Washington University School of Medicine | Other | 1 | ClinicalTrials.gov |
Data dates
The date of each source this release read.
Sources 4
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL
- ClinicalTrials.govNo license stated
- Open TargetsCC0 1.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBLCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this company from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/companies/v1/implicit-bioscience-57e7e6c2
GET https://conductscience.org/api/companies/v1/implicit-bioscience-57e7e6c2/conditions?page=2